×
About 665 results

ALLMedicine™ Becker Muscular Dystrophy Center

Research & Reviews  244 results

Dilated cardiomyopathy as the initial presentation of Becker muscular dystrophy: a syst...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097097
Orphanet Journal of Rare Diseases; Del Rio-Pertuz G, Morataya C et. al.

May 14th, 2022 - There are scarce publications regarding the presentation and outcome of Becker muscular dystrophy in adulthood when idiopathic dilated cardiomyopathy is the initial disease manifestation. We performed a systematic review using Medline, Embase, Coc...

2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in ...
https://doi.org/10.1016/j.hrthm.2022.04.022
Heart Rhythm; Groh WJ, Bhakta D et. al.

May 3rd, 2022 - This international multidisciplinary document is intended to guide electrophysiologists, cardiologists, other clinicians, and health care professionals in caring for patients with arrhythmic complications of neuromuscular disorders (NMDs). The doc...

Body composition and myokines in a cohort of patients with Becker muscular dystrophy (B...
https://doi.org/10.1002/mus.27565
Muscle & Nerve; Barp A, Carraro E et. al.

Apr 28th, 2022 - Becker muscular dystrophy (BMD) is an X-linked disease leading to muscle wasting and weakness. The decrease in lean body mass (LBM) in Duchenne muscular dystrophy, has shown correlation with loss of muscle function and bone density (BD). Myokines ...

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
https://clinicaltrials.gov/ct2/show/NCT05166109

Apr 27th, 2022 - This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight <50 kg) daily administered orally compared...

Health Care Use of Cardiac Specialty Care in Children With Muscular Dystrophy in the Un...
https://doi.org/10.1161/JAHA.121.024722
Journal of the American Heart Association; Mejia EJ, Lin KY et. al.

Apr 13th, 2022 - Background Duchenne and Becker muscular dystrophy are progressive disorders associated with cardiac mortality. Guidelines recommend routine surveillance; we assess cardiac resource use and identify gaps in care delivery. Methods and Results Male p...

see more →

Guidelines  1 results

2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in ...
https://doi.org/10.1016/j.hrthm.2022.04.022
Heart Rhythm; Groh WJ, Bhakta D et. al.

May 3rd, 2022 - This international multidisciplinary document is intended to guide electrophysiologists, cardiologists, other clinicians, and health care professionals in caring for patients with arrhythmic complications of neuromuscular disorders (NMDs). The doc...

see more →

Clinicaltrials.gov  11 results

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
https://clinicaltrials.gov/ct2/show/NCT05166109

Apr 27th, 2022 - This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight <50 kg) daily administered orally compared...

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT03238235

Jan 26th, 2022 - Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses daily while the subject is in fed state, according to the subject's weight. Study drug should be permanently stopped if any of the following occur: severe...

Weekly Steroids in Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT04054375

Jan 19th, 2022 - Glucocorticoid (GC) steroids are a mainstay of therapy for Duchenne Muscular Dystrophy, where they have been shown to prolong ambulation in for DMD in random clinical trials (Gloss et al., 2016). Dosing regimen vary for DMD, but most trials utiliz...

Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
https://clinicaltrials.gov/ct2/show/NCT04349566

Dec 20th, 2021 - The purpose of the study is to explore the biomarker Fast Troponins response to exercise in patients with Becker muscular dystrophy, Limb-girdle muscular dystrophy and McArdle disease

Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
https://clinicaltrials.gov/ct2/show/NCT00847379

Jul 15th, 2020 - This is a Phase 2b, international, multicenter, open-label extension study for participants who successfully completed blinded study drug in Study 007. This extension study will evaluate the long-term administration of ataluren administered 3 time...

see more →

News  7 results

HeartMate 3 OK'd for Destination Tx; Pradaxa Flops in ESUS; Heater-Cooler Infection
https://www.medpagetoday.com/cardiology/prevention/75852

Oct 22nd, 2018 - The HeartMate 3 left ventricular assist device (LVAD) gained an indication for destination therapy. (Star Tribune) Dabigatran (Pradaxa) was no better than aspirin for prevention of recurrent stroke among patients with an embolic stroke of undeterm...

Clinical Outcome Assessments (COA) Qualification Program Submissions
http://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/clinical-outcome-assessments-coa-qualification-program-submissions

The tables below list information about submissions to the FDA Clinical Outcome Assessments (COA) Qualification Program for which final COA qualification determinations have not yet been made. The tables include legacy projects (those submitted pr...

Clinical Outcome Assessments (COA) Qualification Submissions
http://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/clinical-outcome-assessments-coa-qualification-submissions

The tables below list information about submissions to the FDA Clinical Outcome Assessments (COA) Qualification Program for which final COA qualification determinations have not yet been made. The tables include legacy projects (those submitted pr...

Early ACE Inhibitors Can Slow Myocardial Fibrosis Progression in Muscular-Dystrophy Patients
https://www.medscape.com/viewarticle/873078

Dec 8th, 2016 - SÃO PAULO, BRAZIL — Early administration of ACE inhibitors can slow progression of myocardial fibrosis (MF) in youth males with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), according to results of a clinical trial[1]. Dr C...

CHMP Says Renew Conditional Approval of Ataluren for DMD
https://www.medscape.com/viewarticle/871798

Nov 11th, 2016 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended renewal of conditional marketing authorization for ataluren (Translarna, PTC Therapeutics) for treatment of Duchenne muscular dystrophy (DMD)...

see more →

Patient Education  3 results see all →